Switch to Darunavir/r + Maraviroc QD in Patients With R5 Tropism by Viral DNA Genotyping With Suppressed Viremia (GUSTA): a Multicenter, Open-label, Randomized Controlled Trial

Trial Profile

Switch to Darunavir/r + Maraviroc QD in Patients With R5 Tropism by Viral DNA Genotyping With Suppressed Viremia (GUSTA): a Multicenter, Open-label, Randomized Controlled Trial

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 26 Oct 2016

At a glance

  • Drugs Darunavir (Primary) ; Maraviroc (Primary) ; Antiretrovirals; Ritonavir
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms GUSTA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Feb 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 03 Feb 2015 Planned End Date changed from 1 May 2016 to 1 May 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top